GSA Capital Partners LLP Sells 13,465 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

GSA Capital Partners LLP lessened its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 55.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,987 shares of the biopharmaceutical company’s stock after selling 13,465 shares during the period. GSA Capital Partners LLP’s holdings in TG Therapeutics were worth $257,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of TGTX. NBC Securities Inc. lifted its stake in TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in TG Therapeutics in the 2nd quarter valued at approximately $35,000. Blue Trust Inc. lifted its stake in TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 849 shares in the last quarter. ORG Wealth Partners LLC bought a new stake in TG Therapeutics in the 3rd quarter valued at approximately $53,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in TG Therapeutics in the 1st quarter valued at approximately $58,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Up 1.5 %

Shares of TGTX stock opened at $35.07 on Friday. The stock has a market cap of $5.46 billion, a price-to-earnings ratio of -350.66 and a beta of 2.19. The stock has a 50-day moving average of $25.62 and a 200-day moving average of $21.67. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 1-year low of $12.30 and a 1-year high of $36.50.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same period in the previous year, the company posted $0.73 EPS. The company’s quarterly revenue was down 49.4% on a year-over-year basis. On average, equities research analysts forecast that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

Insider Activity

In related news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 10.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on TGTX. HC Wainwright boosted their target price on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. B. Riley upped their price objective on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. The Goldman Sachs Group upped their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, TD Cowen initiated coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.